Advances in the molecular genetics of gliomas

Current Opinion in Oncology

Volumn 9, Issue 3, 1997, Pages 215-222

  Nagane, Motoo ^a   Huang, H J Su ^a   Cavenee, Webster K ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; CANCER GENETICS; CELL CYCLE; CHROMOSOME 10; CHROMOSOME 19Q; CHROMOSOME 22Q; GENE ACTIVATION; GENE MUTATION; GENE REPRESSION; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR GENETICS; ONCOGENE; PRIORITY JOURNAL; REVIEW; STRUCTURAL CHROMOSOME ABERRATION; TUMOR SUPPRESSOR GENE;

EID: 0030841948     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709030-00001     Document Type: Review

References (76)

1. Bögler O, Huang HJS, Kleihues P, Cavenee WK: The p53 gene and its role in human brain tumors. Glia 1995, 15:308-327. A review article providing comprehensive information on the role of p53 alterations in human brain tumors as well as its biochemical and physiological functions.
2. Chen J, Wu X, Lin J, Levine AJ: MDM-2 Inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996, 16:2445-2452. An investigation that reveals the ability of the N-terminal domain of MDM-2 to abrogate both p53-mediated cell cycle arrest and apoptosis.
3. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76:1013-1023.
4. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Multiple polymorphisms, but no mutations in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 1995, 72:1230-1233. A genetic analysis of P21 gene alterations in 158 human brain tumors.
5. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995, 11:2021-2028. A study demonstrating no p21 gene deletion and rather increased p21 expression levels in human gliomas.
6. Hoang-Xuan K, Merel P, Vega F, Hugot JP, Cornu P, Delattre JY, Poisson M, Thomas G, Delattre O: Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. Int J Cancer 1995, 60:478-481.
7. Serrano M, Lee H, Chin L, Cordon CC, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37. A study showing that p16 and p19 knockout mice develop spontaneous tumors at an early age and are susceptible to carcinogens, providing direct evidence that p16 functions to suppress neoplastic growth.
8. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJS: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995, 55:1351-1354.
9. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 1996, 12:103-110.
10. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996, 56:150-153. A genetic investigation of 55 astrocytic gliomas demonstrating that the majority of glioblastomas have alterations of either p16 or Rb, both leading to inactivation of the p16-CDK4-Rb cell cycle regulatory pathway.
11. Sato K, Schauble B, Kleihues P, Ohgaki H: Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1996, 66:305-308. A genetic analysis demonstrating that alterations of the p 15, p16, CDK4, and cyclin D1 genes were rare in 69 nonastrocytic human brain tumors in contrast to those in astrocytic tumors.
12. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072.
13. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Huang HJS: Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 1995, 55:1941-1945.
14. Costello JF, Berger MS, Huang HJS, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996, 56:2405-2410. A study demonstrating hypermethylation of the CpG island in the 5' region of the p16 gene, which causes structural changes of chromatin as an alternative mechanism for p16 inactivation.
15. Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996, 56:722-727. An investigation showing that inactivation of the p15 gene is commonly associated with hypermethylation of the 5'-CpG island in its promoter region in human gliomas.
16. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700-9704.
17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692.
18. Chou D, Miyashita T, Mohrenweiser HW, Ueki K, Kastury K, Druck T, von Deimling A, Huebner K, Reed JC, Louis DN: The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996, 88:136-140. A study in which alterations of the death promoter bax gene were not detected in 20 gliomas with LOH in chromosome 19q, although by somatic cell hybridization and cosmid mapping it maps to chromosome 19q13.3, where a candidate glioma suppressor gene resides.
19. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995, 10:2243-2246.
20. Albarosa R, Colombo BM, Roz L, Magnani I, Pollo B, Cirenei N, Giani C, Conti AM, DiDonato S, Finocchiaro G: Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 1996, 58:1260-1267. An LOH study localizing tumor suppressor gene regions on chromosome 10q, whose deletion is involved in the development of glioblastoma.
21. Albarosa R, DiDonato S, Finocchiaro G: Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. Hum Genet 1995, 95:709-711.
22. Collins VP: Gene amplification in human gliomas. Glia 1995, 15:289-296 A review article providing information about gene amplification that occurs in human gliomas, including EGFR gene and the amplicon in chromosome 12q13-14.
23. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994, 91:7727-7731.
24. Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling. J Biol Chem 1997, 272:2927-2935 An investigation indicating that weak and unattenuated constitutive tyrosine kinase activity of a truncated mutant EGFR contributes to its enhanced tumorigenic activity in human glioblastoma cells.
25. 1.
26. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996, 271:25639-25645. A molecular analysis showing that the constitutively activated mutant EGFR commonly overexpressed in glioblastomas signals through activation and association of She, Grb2 and Ras, thereby mediating its growth advantage.
27. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek T, Wong AJ, Zalutsky MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55:3140-3148.
28. Hills D, Rowlinson BG, Gullick WJ: Specific targeting of a mutant activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 1995, 63:537-543. A study in which a specific monoclonal antibody against a truncated EGFR was raised and used for targeting of the receptor expressed in tumors in nude mice.
29. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJS: Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 1996, 56:3859-3861. A biological analysis demonstrating that a tyrosine kinase inhibitor, tyrphostin AG 1478. preferentially suppresses the constitutive phosphorylation of a mutant truncated EGFR relative to ligand-dependent autophosphorylation of wild type EGFR, resulting in preferential inhibition of growth and proliferation rate of glioma cells expressing the mutant receptor.
30. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A, Nister M: Association of loss of heterozygosity on chromosome 17p with high plateletderived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 1996, 56:164-171. An investigation that correlates high expression of PDGF receptor-α with LOH on chromosome 17p in low- and high-grade astrocytomas.
31. Feuerstein BG, Mohapatra G: Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas. J Neurooncol 1995, 24:47-55.
32. Weber RG, Sabel M, Reifenberger J, Sommer C: Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996, 13:983-994. An analysis of 30 human primary and recurrent gliomas from 15 patients by comparative genomic hybridization providing a comprehensive overview of the genomic alterations associated with the progression of individual gliomas.
33. He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of CDK4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995, 55:4833-4836. An investigation showing alternative mechanisms leading to the functional inactivation of retinoblastoma protein in the majority of human gliomas.
34. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Huang HJS, Cavenee WK: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997, 57:1250-1254.
35. White E: Life, death, and the pursuit of apoptosis. Genes Dev 1996, 10:1-15. An outstanding review of apoptosis that provides comprehensive understanding of the roles of apoptosis regulators in process of cell death at the biochemical level.
36. Gomez MC, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996, 56:694-699. A functional analysis of the wild-type p53 gene delivered by an adenovirus vector, demonstrating that apoptosis is induced in the glioma cells expressing endogenous mutant p53, while cell proliferation is inhibited in cells with wild-type p53 genotype.
37. Yount GL, Haas KD, Vidair CA, Haas M, Dewey WC, Israel MA: Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 1996, 56:500-506. An investigation revealing that p53-dependent G1 arrest, but not apoptosis, is induced by ionizing radiation, contributing to radiosensitivity of glioma cells.
38. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev 1996, 10:1054-1072. An excellent review of p53 disclosing recent studies on its structure, functions and biological roles in cells and tumorigenesis.
39. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
40. Owen-Schaub L, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995, 15:3032-3040.
41. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yen H, Hoeijmakers JH, Harris CC: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996, 10:1219-1232. An investigation demonstrating a novel pathway of p53-mediated apoptosis that may require the carboxyl terminus of p53 associated with the DNA helicases, XPB, and XPD.
42. Caelles C, Helmberg A, Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994, 370:220-223.
43. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M: Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995, 9:2170-2183. A study supporting the idea that p53 can induce apoptosis independent of its transcriptional transactivation ability.
44. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S: Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996, 69:236-240. An investigation demonstrating that p53 mutations detected in clinical specimens of human malignant gliomas were associated with decreased sensitivity to various chemotherapeutic agents, suggesting that p53 mutation may predispose to cell killing via chemotherapy in malignant gliomas.
45. L to protect cancer cells from apoptosis induced by wild type p53 expression.
46. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995, 95:2633-2643.
47. L act upstream of these proteases.
48. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 1995, 6:363-370.
49. L in tumor cells protects them from apoptosis induced by a variety of chemotherapeutic agents, but does not prevent cells from undergoing cell cycle arrest.
50. Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg 1995, 83:1017-1022.
51. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, Loh DY: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995, 267:1506-1510.
52. Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A: Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-α. Embo J 1996, 15:3861-3870.
53. Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995, 375:78-81.
54. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R: Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. Embo J 1995, 14:5859-5868.
55. Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299-308. A molecular investigation demonstrating that TNF receptor-1-TRADD signaling pathways are mediated through both FADD (that induces apoptosis) and TRAF2 (that activates NF-κB).
56. Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996, 274:782-784. A key study demonstrating a role of NF-κB in preventing the apoptosis induced by TNF-α.
57. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines. J Clin Invest 1994, 94:954-964.
58. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 1995, 55:5528-5530. A reverse transcription-polymerase chain reaction-based analysis of Fas mRNA expression in 34 astrocytic tumors demonstrating the correlation between the frequency of Fas expression and the malignancy grade of tumors.
59. Darmon AJ, Nicholson DW, Bleackley RC: Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995, 377:446-448.
60. Martin SJ, Green DR: Protease activation during apoptosis: death by a thousand cuts? Cell 1995, 82:349-352.
61. L, suggesting that ICE may mediate apoptosis induced by chemotherapy.
62. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364. An outstanding review concerning the roles and mechanisms of angiogenesis in tumorigenesis and providing information on the angiogenic switch that is balanced by angiogenic activators and inhibitors.
63. Leon SP, Folkerth RD, Black PM: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996, 77:362-372. A clinicopathologic investigation in which correlation between the microvessel density of astroglial tumors with survival rate of the patients was shown.
64. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 1995, 15:339-347. A review article containing information on glioma angiogenesis, chiefly focusing on involvement of VEGF and its receptors system in glioma progression.
65. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439. A study of VEGF knockout mice demonstrating that a heterozygous VEGF-deficiency causes severe impairment of vasculogenesis and resultant embryonic lethality, indicating a crucial role of VEGF in normal vascular development.
66. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56:2185-2190. A study of VEGF concentrations in sera and tumors of 19 patients with brain tumor showing that the tumor tissue of glioblastomas contained significantly higher VEGF than other types of tumors as well as normal brain, but that its serum concentration was not correlated with that of tissue.
67. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 270:19761-19766.
68. Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 1996, 271:25492-25497. A molecular analysis in which hypoxia-inducible proteins were shown to stabilize VEGF mRNA by forming RNA-protein complexes, and showing that the complex and VEGF mRNA stability were constitutively elevated in cells lacking tumor suppressor VHL gene.
69. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny BG, Marme D: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996, 56:2299-2301. A functional analysis demonstrating that restoration of wild-type VHL gene reverted deregulated expression of VEGF in renal cell carcinoma cells that either lacked endogenous wild-type VHL or expressed an inactive mutant VHL.
70. Cheng SY, Huang HJS, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93:8502-8507. An investigation in which antisense VEGF RNA was shown to effectively inhibit angiogenic and tumorigenic activities of human glioblastoma cells in vivo.
71. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996, 56:393-401. An investigation in which antisense VEGF RNA was shown to effectively inhibit angiogenic and tumorigenic activities of rat glioblastoma cells in vivo.
72. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56:3540-3545.
73. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
74. Van Meir EG, Polverini PJ, Chazin VR, Huang HJS, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994, 8:171-176.
75. von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 1995, 15:328-338. A review article providing extensive information on molecular genetic alterations that occur during glioma progression and proposing distinct genetic pathways that result in formation of glioblastomas.
76. Furnari FB, Huang HJS, Cavenee WK: Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg 1996, 24:41-49. A review article summarizing the stage-specific genetic lesions of glioma progression.